Precision Biosciences (DTIL) Change in Accured Expenses (2018 - 2026)

Precision Biosciences (DTIL) has 9 years of Change in Accured Expenses data on file, last reported at -$1.8 million in Q1 2026.

• On a quarterly basis, Change in Accured Expenses rose 64.91% year-over-year to -$1.8 million in Q1 2026; TTM through Mar 2026 was $1.6 million, a 210.72% increase from a year earlier, with the FY2025 full-year figure at -$1.8 million, up 17.2% from the prior year.
• Change in Accured Expenses for Q1 2026 stood at -$1.8 million, down from $2.2 million in the prior quarter.
• Over the last five years, Change in Accured Expenses for DTIL reached as high as $2.4 million in Q2 2022 and fell as low as -$5.8 million in Q1 2024.
• Historically, Change in Accured Expenses has averaged -$483882.4 across 5 years, with a median of $474000.0 in 2022.
• Across the five-year window, Change in Accured Expenses plunged 139.98% in 2022 and jumped 1478.85% in 2025, its largest moves.
• Year by year, Change in Accured Expenses stood at $421000.0 in 2022, then surged by 464.61% to $2.4 million in 2023, then plunged by 106.56% to -$156000.0 in 2024, then soared by 1478.85% to $2.2 million in 2025, then slumped by 183.5% to -$1.8 million in 2026.
• Per Business Quant data, the three most recent Change in Accured Expenses figures were -$1.8 million in Q1 2026, $2.2 million in Q4 2025, and $528000.0 in Q3 2025.